BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 8772700)

  • 1. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction.
    Anand S; Diamond SL
    Circulation; 1996 Aug; 94(4):763-74. PubMed ID: 8772700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inner clot diffusion and permeation during fibrinolysis.
    Diamond SL; Anand S
    Biophys J; 1993 Dec; 65(6):2622-43. PubMed ID: 8312497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis.
    Wu JH; Siddiqui K; Diamond SL
    Thromb Haemost; 1994 Jul; 72(1):105-12. PubMed ID: 7974357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
    Wootton DM; Popel AS; Alevriadou BR
    Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme-mediated proteolysis of fibrous biopolymers: Dissolution front movement in fibrin or collagen under conditions of diffusive or convective transport.
    Anand S; Wu JH; Diamond SL
    Biotechnol Bioeng; 1995 Oct; 48(2):89-107. PubMed ID: 18623465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts.
    Zhalyalov AS; Panteleev MA; Gracheva MA; Ataullakhanov FI; Shibeko AM
    PLoS One; 2017; 12(7):e0180668. PubMed ID: 28686711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion.
    Anand S; Kudallur V; Pitman EB; Diamond SL
    Ann Biomed Eng; 1997; 25(6):964-74. PubMed ID: 9395042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
    Kajimoto Y; Ohta T; Kuroiwa T
    Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
    Pieters M; Hekkenberg RT; Barrett-Bergshoeff M; Rijken DC
    Ultrasound Med Biol; 2004 Nov; 30(11):1545-52. PubMed ID: 15588966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
    Mutch NJ; Moore NR; Wang E; Booth NA
    J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico study of combination thrombolytic therapy with alteplase and mutant pro-urokinase for fibrinolysis in ischemic stroke.
    Yang Y; Gu B; Xu XY
    Comput Biol Med; 2024 Mar; 171():108141. PubMed ID: 38367449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
    Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT; Francis CW; Marder VJ
    J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a multi-physics modelling framework for thrombolysis under the influence of blood flow.
    Piebalgs A; Xu XY
    J R Soc Interface; 2015 Dec; 12(113):20150949. PubMed ID: 26655469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
    Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
    Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.